The Life Science venture fund Eir Ventures today announced a first closing of its new fund of €76 million. With a strong base in the Nordic region and a team of experienced life science investors, Eir Ventures will invest in innovative European companies with products and technologies addressing significant unmet medical need and a potential to improve the life of patients. The fund is launched with support from a investor syndicate comprising Saminvest, the European Investment Fund (EIF), Vækstfonden, Novo Holdings, as well as additional private investors.
Eir Ventures has been set up by an experienced team of life science investors, including Magnus Persson, Stephan Christgau, Andreas Segerros as the Managing Partners, and Amanda Hayward as Special Partner. With offices in Stockholm and Copenhagen, Eir Ventures will invest in high return potential opportunities in the Nordics, Europe and the US. The fund will have a particular focus on innovations from the leading universities and incubators in the Nordics and has established collaborations with select Nordic Universities.
Magnus Persson, Managing Partner of Eir Ventures, commented: “In the current environment, where financing has become even more sparse and startups are struggling to fund development, healthcare innovation is more important than ever. We see great potential to bring some of the highly innovative treatments to patients with underserved medical needs, while also bringing outstanding returns to our investors.”